BioMimetic Therapeutics, Inc. to Report Third Quarter 2012 Financial Results on November 5

BioMimetic Therapeutics, Inc. to Report Third Quarter 2012 Financial Results on November 5

FRANKLIN, Tenn.--(BUSINESS WIRE)-- BioMimetic Therapeutics, Inc. (NAS: BMTI) today announced that the Company plans to release its financial results for the three and nine months ended September 30, 2012, on Monday, November 5 after the close of market. The Company will host a conference call and audio webcast to discuss its third quarter financial results, product development programs and business activities at 4:30 p.m. EST the same day.

The conference call may be accessed on November 5, 2012, by dialing (877) 224 - 4059 for U.S. and Canadian callers (passcode:56458053). The international dial in number is (706) 902 - 2069, and the same passcode applies. Participants should dial in 10 minutes prior to the call.

A live webcast of the conference call will be available on the Investor Relations section of BioMimetic's website at The webcast will be archived for at least 30 days following the call.

About BioMimetic Therapeutics

BioMimetic Therapeutics (NAS: BMTI) is a biotechnology company specializing in the development and commercialization of clinically proven products to promote the healing of musculoskeletal injuries and diseases, including therapies for orthopedics, sports medicine and spine applications. All Augment® branded products are based upon recombinant human platelet-derived growth factor (rhPDGF-BB), which is an engineered form of PDGF, one of the body's principal agents to stimulate and direct healing and regeneration. Through the commercialization of this patented technology, BioMimetic seeks to become the leading company in the field of regenerative medicine by providing new treatment options for the repair of bone, cartilage, tendons and ligaments.

BioMimetic has received regulatory approvals to market Augment® Bone Graft in Canada, Australia and New Zealand for use in foot and ankle fusion indications. Augment is pending regulatory decisions in the U.S. and European Union for similar indications. The Company also markets a bone graft substitute line of products for orthopedic indications called AugmatrixTM Biocomposite Bone Graft.

For further information, contact Kearstin Patterson, senior director of corporate communications, at 615-236-4419.

BioMimetic Therapeutics, Inc.
Kearstin Patterson
Corporate Communications
615-236-4419 (office)
615-517-6112 (mobile)

KEYWORDS: United States North America Tennessee


The article BioMimetic Therapeutics, Inc. to Report Third Quarter 2012 Financial Results on November 5 originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.